CN108272814A - A kind of composition and its application containing cordycepin - Google Patents
A kind of composition and its application containing cordycepin Download PDFInfo
- Publication number
- CN108272814A CN108272814A CN201810394808.0A CN201810394808A CN108272814A CN 108272814 A CN108272814 A CN 108272814A CN 201810394808 A CN201810394808 A CN 201810394808A CN 108272814 A CN108272814 A CN 108272814A
- Authority
- CN
- China
- Prior art keywords
- cordycepin
- composition
- present
- nuciferine
- obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 title claims abstract description 45
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 title claims abstract description 44
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 claims abstract description 27
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 claims abstract description 27
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 claims abstract description 27
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 20
- 208000008589 Obesity Diseases 0.000 claims abstract description 19
- 235000020824 obesity Nutrition 0.000 claims abstract description 19
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 14
- 239000006187 pill Substances 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 239000003405 delayed action preparation Substances 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- -1 oral solution Substances 0.000 claims description 6
- 229940100688 oral solution Drugs 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 12
- 150000002632 lipids Chemical class 0.000 abstract description 10
- 108010060263 Adenosine A1 Receptor Proteins 0.000 abstract description 9
- 102000030814 Adenosine A1 receptor Human genes 0.000 abstract description 9
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract description 7
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 7
- 210000002966 serum Anatomy 0.000 abstract description 6
- 102000004169 proteins and genes Human genes 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 102000004895 Lipoproteins Human genes 0.000 abstract description 4
- 108090001030 Lipoproteins Proteins 0.000 abstract description 4
- 230000005856 abnormality Effects 0.000 abstract description 4
- 238000009825 accumulation Methods 0.000 abstract description 3
- 230000006651 lactation Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 21
- 230000000694 effects Effects 0.000 description 14
- 241000700159 Rattus Species 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- 229940023488 pill Drugs 0.000 description 11
- 241000712461 unidentified influenza virus Species 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000003946 Prolactin Human genes 0.000 description 6
- 108010057464 Prolactin Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 229940097325 prolactin Drugs 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RIRGCFBBHQEQQH-SSFGXONLSA-N (-)-n6-(2-phenylisopropyl)adenosine Chemical compound C([C@@H](C)NC=1C=2N=CN(C=2N=CN=1)[C@H]1[C@@H]([C@H](O)[C@@H](CO)O1)O)C1=CC=CC=C1 RIRGCFBBHQEQQH-SSFGXONLSA-N 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 102100033346 Adenosine receptor A1 Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- FFBDFADSZUINTG-UHFFFAOYSA-N DPCPX Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1CCCC1 FFBDFADSZUINTG-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000002582 adenosine A1 receptor agonist Chemical group 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 101710128948 Adenosine receptor A1 Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000799712 Homo sapiens Adenosine receptor A1 Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- PFRUBEOIWWEFOL-UHFFFAOYSA-N [N].[S] Chemical compound [N].[S] PFRUBEOIWWEFOL-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940125400 channel inhibitor Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229910021424 microcrystalline silicon Inorganic materials 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- JKQOBWVOAYFWKG-UHFFFAOYSA-N molybdenum trioxide Chemical compound O=[Mo](=O)=O JKQOBWVOAYFWKG-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 150000006636 nicotinic acid Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a kind of compositions containing cordycepin, belong to field of traditional Chinese.The composition of the present invention includes the raw material of following parts by weight：0.1~3 part of cordycepin, 1~12 part of Nuciferine, composition compatibility of the present invention is simple, and raw material sources are extensive, can significantly reduce white adipose accumulation, serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) content can be such that high-density lipoprotein (HDL) content significantly increases, GH3 cell adenosine A 1 receptors can also be induced to be increased on protein level, significantly inhibit the lactation release of GH3 cells.As it can be seen that the composition provided by the invention containing cordycepin can simultaneously pre- preventing obesity, lose weight, preventing/treating hyperlipidemia, adjust lipoprotein abnormalities, adjust lipid metaboli, reduce coronary heart disease incidence.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicine preparation, and in particular to a kind of compsn. consisting of influenza virus surface and its application.
Background technology
Obesity can lead to a series of metabolic diseases, such as diabetes, hypertension, hyperlipidemia, fatty liver and certain
Cancer etc., therefore it has been the fifth-largest lethal factor in the whole world.It is very few to can be clinically used for the fat drug for the treatment of at present,
And safety and curative effect there is no final conclusion.Fat pathogenesis is complicated, there is no a good drug target, slimming drugs at present
In object development process, many drugs are all played a role by acting on neural feeding center, because various side effects can not be wide
General application.
Clinically so-called hyperlipidemia (Hyperlipidemia, HLP) is primarily referred to as cholesterol and is higher than 200mg/
100ml, triglycerides are higher than 150mg/100ml.Hyperlipidemia is a kind of common angiocardiopathy, mainly due to blood fat generation
Caused by thanking to disorder, still result in atherosclerosis, hypertension, coronary heart disease, diabetes, cholelithiasis chronic diseases it is main because
Element seriously threatens human health.Drug currently used for treating hyperlipidemia is mostly Western medicine, mainly there is four classes：(1) benzene oxygen
Aromatic acids (fibrates), there is fenofibrate, Gemfibrozil Capsules, Bezafibrate etc., their effect for reducing blood fat are strong, rapid-action, sweet to drop
Based on oily three esters；(2) trihydroxy methyl glutaryl-CoA-reductase inhibitors (Statins) have Lovastatin, Simvastatin, general
Statin etc. is cut down, based on norcholesterol；(3) niacin class, have niacin, asimo this etc., have drop to triglycerides and cholesterol
Low effect；(4) cholic acid chelating agent (resinae), there is Cholestyramine and Colestipol, reduces the absorption of intestinal cholesterol, increases liver
Utilization of the cell to cholesterol reduces cholesterol.But these drugs are while lipid-loweringing, it will usually cause blood glucose rise, nausea,
Abdominal distension, abdominal pain, diarrhea, constipation, headache, insomnia, weak, fash, itching, hidrosis, myalgia, rhabdomyolysis and liver function energy loss
A variety of adverse reactions such as evil.
In addition, hypertension can lead to coronary atherosclerosis, and played extremely during coronary heart disease occurrence and development
Important role.Long-term blood pressure raising can cause left ventricular hypertrophy and myocardial fibrosis, make coronary flow supply that obstacle occur,
Influence Coronary reserve ability.The drug of the high blood pressure of doctor trained in Western medicine prevention at present mainly has angiotensin converting enzyme inhibitors,
Angiotensin II receptor antagonist, beta receptor inhibitor, calcium channel inhibitor (are divided into as dihydropyridines, phenyl alkylamide and sulphur
Nitrogen Zhuo class three classes), diuretics (is divided into thiazide, loop diuresis, protects potassium diuresis and four class of sulfamido).Using this disease of western medicine
Although achieving certain curative effect, the side effect of Western medicine is bigger, and especially gerontal patient can suffer from kidney function energy loss simultaneously
Wound, diabetes etc. are unable to long-term, high-dose and take Western medicine.Although also there is part Chinese medicine preparation, Chinese medicine preparation compatibility is complicated,
It is efficient low.
At present still without it is a kind of can simple compatibility Chinese medicine preparation, can have simultaneously to obesity, hyperlipidemia, coronary heart disease
Effect.
Invention content
In view of this, the purpose of the present invention is to provide a kind of composition containing cordycepin, can apparent pre- preventing obesity, mitigate
Weight, preventing/treating hyperlipidemia adjust lipoprotein abnormalities, adjust lipid metaboli, reduce coronary heart disease incidence.
In order to achieve the above-mentioned object of the invention, the present invention provides following technical scheme：
The present invention provides a kind of compositions containing cordycepin, include the raw material of following parts by weight：1~12 part of Nuciferine,
0.1~3 part of cordycepin.
Preferably, include the raw material of following parts by weight：0.2~2 part of cordycepin, 2~10 parts of Nuciferine.
The present invention provides a kind of above-mentioned compositions to prepare prevention and/or treatment obesity, hyperlipidemia, coronary heart disease medicine
Application in object.
Preferably, the dosage form of the drug includes tablet, capsule, granule, pill, pill, oral solution, sugar
Starch agent and sustained-release preparation.
The present invention provides a kind of above-mentioned compositions to have auxiliary treatment work in preparation to obesity, hyperlipidemia and coronary heart disease
Application in food.
Preferably, the food includes ordinary food and health products.
The present invention provides a kind of above-mentioned compositions to have auxiliary treatment work in preparation to obesity, hyperlipidemia and coronary heart disease
Application in cosmetics.
The present invention provides a kind of compositions containing cordycepin, and compatibility is simple, and cordycepin, which has, to be prevented due to high fat diet
Caused obesity, Nuciferine have the function of that, obviously in losing weight, raw material sources are extensive.Embodiment the result shows that, compare
In model control group, whole weight loss 14%, fat coefficient reduces by 33%, can significantly reduce white adipose accumulation, the total courage of serum
Sterol (TC) content declines 48%, and triglyceride (TG) content reduces by 41.6%, and low-density lipoprotein (LDL) content reduces
48%, high-density lipoprotein (HDL) content improves 136.4%, additionally it is possible to induce GH3 cell adenosine A 1 receptors on protein level
It increases, significantly inhibits the lactation release of GH3 cells.As it can be seen that promotor composition containing cordyceps sinensis provided by the invention can simultaneously pre- preventing obesity,
It loses weight, preventing/treating hyperlipidemia adjusts lipoprotein abnormalities, adjusts lipid metaboli, reduces coronary heart disease incidence.
Description of the drawings
Fig. 1 is the compsn. consisting of influenza virus surface that provides of the embodiment of the present invention 11 to rat pituitary cell GH3 proliferation-toxicity
Function influence result figure；
Fig. 2 is that the compsn. consisting of influenza virus surface that the embodiment of the present invention 11 provides makees the expression of adenosine receptor A 1 in GH3 cells
With influence result figure；
Fig. 3 is the influence result that the compsn. consisting of influenza virus surface that the embodiment of the present invention 11 provides synthesizes prolactin(PRL and discharges
Figure.
Specific implementation mode
The present invention provides a kind of compositions containing cordycepin, include the raw material of following parts by weight：1~12 part of Nuciferine,
0.1~3 part of cordycepin.
In compsn. consisting of influenza virus surface of the present invention, the parts by weight of cordycepin are preferably 0.2~2 part, more preferably
0.5~1.2 part, most preferably 1 part.Cordycepin of the present invention can prevent fat caused by high fat diet.The present invention is to institute
Stating the source of cordycepin, there is no particular determinations, preferably sintetics or self-carry product, when for sintetics, the conjunction
A kind of synthetic methods of cordycepin of Chinese patent CN201410335858.3 are preferably referred at the preparation method of product；When for certainly
When carrying product, Cordyceps militaris or cordyceps flower are preferably extracted from, is extracted after biofermentation.Extraction of the present invention to the self-carry
There is no particular determinations for method, utilize the general extraction methods of this field.
In compsn. consisting of influenza virus surface of the present invention, the parts by weight of Nuciferine are preferably 2~10 parts, more preferably 3
~6 parts, most preferably 4 parts.Heretofore described Nuciferine can play the effect to lose weight.The present invention is to the Nuciferine
Source there is no particular determination, from extraction or commercial product, purity ＞ 98% is measured through HPLC.
The present invention provides application of the above-mentioned composition in preparing prevention and/or obesity treating medicine.The present invention couple
There is no particular determinations for the dosage form for preventing obesity drug, include preferably tablet, capsule, granule, pill, dripping pill
Agent, oral solution, syrup and sustained-release preparation.
The present invention provides above-mentioned compositions in preparing prevention and/or treatment obesity, hyperlipidemia, medicaments for coronary disease
Application.The present invention to it is described prevention and/or treatment obesity, hyperlipidemia, there is no special limits for the dosage form of medicaments for coronary disease
It is fixed, include preferably tablet, capsule, granule, pill, pill, oral solution, syrup and sustained-release preparation.
The present invention provides above-mentioned compositions to have auxiliary therapeutic action in preparation to obesity, hyperlipidemia and coronary heart disease
Application in food.Food of the present invention includes preferably health products and ordinary food.Agent of the present invention to the health products
There is no particular determinations for type, preferably include tablet, capsule, granule, pill, pill, oral solution, syrup and
Sustained-release preparation.
The present invention provides above-mentioned compositions to have auxiliary therapeutic action in preparation to obesity, hyperlipidemia and coronary heart disease
Application in cosmetics.There is no particular determinations for type of the present invention to the cosmetics, include preferably emplastrum.
Compsn. consisting of influenza virus surface provided by the invention is described in detail with reference to embodiment, but cannot be it
Be interpreted as limiting the scope of the present invention.
Embodiment 1
0.5g cordycepins and 2.0g Nuciferines are weighed, after mixing, obtains feedstock composition；Vitamin C, fruity is added
Essence, taurine, sterilizing cross 200 mesh sieve, you can as raw-food material.
Embodiment 2
1g cordycepins and 4g Nuciferines are weighed, after mixing, obtains composition；
According to traditional cream manufacture craft, above-mentioned active compound and stearic acid, lanolin, atoleine, all is added
Intellectual circle, you can prepare medicinal external emulsifiable paste.
Above-mentioned emulsifiable paste can specific aim elimination abdominal obesity.
Embodiment 3
1g cordycepins and 4g Nuciferines are weighed, after mixing, obtains composition；
According to conventional emplastrum manufacture craft, Sodium Polyacrylate, carboxylic first fiber rope sodium, bright is added into above-mentioned composition
Glue, glycerine and superfine silica gel powder, you can prepare emplastrum.
Above-mentioned emplastrum can specific aim elimination abdominal obesity.
Embodiment 4
1g cordycepins and 4g Nuciferines are weighed, after mixing, obtains composition；
According to conventional tablet, buccal tablet technique, above-mentioned composition and cane sugar powder, mannitol, sorbierite is added, you can system
Standby piece agent.
The human body taking dose of recommendation is：Cordycepin 1.98-8.36mg/kg/d；Nuciferine 7.9-33.44mg/kg/d.
Embodiment 5
0.5g cordycepins and 2g Nuciferines are weighed, after mixing, obtains composition；
According to conventional hard capsule preparation process, above-mentioned active compound and mannitol, microcrystalline cellulose, stearic acid is added
Magnesium, cross-linked cellulose, mannitol, you can be prepared into hard capsule.
The human body taking dose of recommendation is：Cordycepin 1.98-8.36mg/kg/d；Nuciferine 7.9-33.44mg/kg/d.
Embodiment 6
3g cordycepins and 12g Nuciferines are weighed, after mixing, obtains composition；
According to conventional soft capsule agent formulation technique, above-mentioned active compound and PEG-400, glycerine, glycerine, oxidation is added
Iron, sucrose, you can be prepared into soft capsule.
The human body taking dose of recommendation is：Cordycepin 1.98-8.36mg/kg/d；Nuciferine 7.9-33.44mg/kg/d.
Embodiment 7
1.5g cordycepins and 6g Nuciferines are weighed, after mixing, obtains composition；
According to conventional granulates agent agent formulation technique, above-mentioned active compound and starch is added, lactose, pregelatinized starch, gathers
Ethylene glycol, microcrystalline silicon, you can be prepared into granule.
The human body taking dose of recommendation is：Cordycepin 1.98-8.36mg/kg/d；Nuciferine 7.9-33.44mg/kg/d.
Embodiment 8
0.9g cordycepins and 3.6g Nuciferines are weighed, after mixing, obtains composition；
According to conventional Bolus formulation technique, above-mentioned active compound and honey, beeswax, batter, wine, sucrose is added, you can
It is prepared into pill.
The human body taking dose of recommendation is：Cordycepin 1.98-8.36mg/kg/d；Nuciferine 7.9-33.44mg/kg/d.
Embodiment 9
0.25g cordycepins and 1g Nuciferines are weighed, after mixing, obtains composition；
According to conventional pill preparation process, above-mentioned active compound and PEG-4000/6000, odium stearate, hard is added
Resin acid, glycerin monostearate, you can be prepared into pill.
The human body taking dose of recommendation is：Cordycepin 1.98-8.36mg/kg/d；Nuciferine 7.9-33.44mg/kg/d.
Embodiment 10
1g cordycepins and 4g Nuciferines are weighed, after mixing, obtains composition；
According to traditional oral solution, syrup formulation technique, be added above-mentioned active compound and sucrose, sodium alginate,
Arabic gelatin, chitosan, p-hydroxybenzoate, you can be prepared into syrup.
The human body taking dose of recommendation is：Cordycepin 1.98-8.36mg/kg/d；Nuciferine 7.9-33.44mg/kg/d.
Embodiment 11
2.5g cordycepins and 10g Nuciferines are weighed, after mixing, obtains composition；
According to conventional slow control formula preparation process, above-mentioned active compound and ethyl cellulose, sodium oxide molybdena, lactose, hydroxyl is added
Third methylcellulose, beeswax, glucose, pectin, you can be prepared into sustained-release preparation.
The human body taking dose of recommendation is：Cordycepin 1.98-5.57mg/kg/d；Nuciferine 7.9-22.29mg/kg/d.
Drug, health products, the foods and cosmetics being prepared using embodiment 1~11 are tested：
1, rat body weight and fat coefficient experiment
Experimental animal and feed：SD rats 50, male, cleaning grade, 180~200g of weight, by the Chinese People's Liberation Army
Military Medical Science Institute's Experimental Animal Center, experimental animal use credit number： SCXK2015-0001.Test the feed used
For 60% high lipid food (Research diets, the U.S.).
Establish model：After a week by rat adaptable fed, it weighs, 20 experimental animals is randomly divided into 2 groups, every group 10
Only, blank control group gives basal feed, and model group gives high lipid food, after continuous feeding 35d, after fasting 12h, is given in last
Weigh after medicine 1h, docking takes blood, and serum is collected after blood room temperature 2h, 3000r/min centrifugation 30min, for detect TC,
Tetra- blood lipids index of TG, LDL, HDL, and after rat anesthesia is put to death, take intraperitoneal white adipose to weigh, and calculate fat
Coefficient.
10 normal mouses are selected as Normal group, 10 model mices are according to cordycepin 50mg/kg/d, lotus leaf
The amount gavage of alkali 200mg/kg/d is poured water according to the amount of 250mg/kg/d as model pair as experimental group, 10 model mices
According to group, in the case of remaining condition all same, after feeding 35d, the results are shown in Table 1：
The influence for the obese rat weight that composition of the table 1. containing cordycepin induces high fat diet
Note：In 0.01 levels of P ＜, there were significant differences compared with Normal group for " ## " expression model control group, and " * * " is indicated
Experimental group indicates experimental group compared with model group in P ＜ compared with model group in the horizontal significant differences of P ＜ 0.01, " * "
There were significant differences for 0.05 level.
As a result it shows：Compared with Normal group, model control group weight is significantly higher than Normal group and experimental group, and
And the white adipose accumulation in experimental group body is considerably less than model control group.
2, the detection of rat blood serum lipid level, testing result are as shown in table 2：
The influence for the obese rat lipid metaboli that composition of the table 2. containing cordycepin induces high fat diet
As a result it shows：Compared with Normal group, TC, TG, LDL content have notable liter in model control group rat blood serum
Height, HDL are significantly reduced；Compared with model control group, experimental group TC, TG, LDL are significantly reduced；With model control group group ratio
Compared with experimental group HDL is significantly increased.
3, compsn. consisting of influenza virus surface is to rat pituitary oncocyte GH3 cell Proliferations-toxic effect GH3 rat pituitaries
Tumor cell strain (purchased from hundred fervent Bioisystech Co., Ltd of match), uses ham ' s F12k【Containing heat-inactivated 2.5% fetal calf serum
(BI) and 15% horse serum (MRC), 100U/mL penicillin, 100 μ g/mL streptomysins】Medium culture, is placed in 37 DEG C, 5%
It is cultivated in CO2 incubators, replaces a subculture within two days.Using the good cell of logarithmic phase growth conditions, with 1 × 104/ hole connects
After culture for 24 hours, cordycepin, Nuciferine (25~100 μ g/mL, 100~400 μ g/ of various concentration are added in 96 orifice plates in kind
ML) after culture for 24 hours, after 10 μ l CCK-8 solution effects 4h are added, the absorbance at 450nm is measured with microplate reader.
Test result is as shown in Figure 1：Cordycepin, the Nuciferine of various concentration act on GH3 cells for 24 hours, cordycepin：Nuciferine
Combination is in 100 μ g/mL：The survival rate of cell is 75% when 400 μ g/mL, 50 μ g/mL：Survival rate is 87% when 200 μ g/mL,
In cordycepin：Nuciferine is less than 25 μ g/mL：Survival rate is 100% when 100 μ g/mL.
4, compsn. consisting of influenza virus surface is to adenosine A 1 receptor (ADORA1) expressional function in GH3 cells
By the GH3 cells of culture to logarithmic phase with 1 × 106The density in/hole is seeded in 6 porocyte culture plates, is added not
With concentration cordycepin, Nuciferine combination (6.25：25、12.5:50、25:100 μ g/mL μ g/mL) effect 2h after, collect cell,
Total protein of cell is extracted, after BCA methods measure albumen concentration, the albumen of equivalent is subjected to PAGE gel electrophoresis, with half-dried turn
Method is by protein delivery to PVDF films, and with 2h is closed on 5% skimmed milk power room temperature shaker, primary antibody was incubated under the conditions of 4 DEG C
Night is washed three times with TBST, each 10min, and secondary antibody is washed after film to be protected from light with ECL chemical luminescence for liquid and be incubated in closing 2h under room temperature
2min is educated, using chemiluminescence imaging system acquisition image, gray value is calculated and analyzes expressing quantity.
Experimental result is as shown in Figure 2：The cordycepin of various concentration, Nuciferine combination (6.25：25、12.5:50、 25:100
μ g/mL) GH3 cell adenosine A 1 receptor protein expressions can be induced to increase, explanation can induce GH3 cell adenosine A 1 receptors
It is significantly increased on protein level, and the expression quantity highest in 25 μ g/mL of cordycepin, 100 μ g/mL of Nuciferine.
5, the influence that compsn. consisting of influenza virus surface synthesizes prolactin(PRL and discharges
By the GH3 cells of culture to logarithmic phase with 1 × 106The density in/hole is seeded in 6 porocyte culture plates, waits for cell
The culture solution more renewed after adherent, setting blank group, adenosine A 1 receptor inhibitor group (DPCPX), adenosine A 1 receptor inhibitor+
Cordycepin group, adenosine a1 receptor agonists group (R-PIA) after different drug effects is added for 24 hours, collect cells and supernatant,
The content of prolactin(PRL in cell conditioned medium is detected with ELISA kit.
Experimental result is as shown in Figure 3：Compared with the control group, the cordyceps sinensis of adenosine a1 receptor agonists (R-PIA), various concentration
Element, Nuciferine combination (6.25：25、12.5:50、25:100 μ g/mL) can significantly inhibit GH3 cells lactation release；Gland
Glycosides A1 acceptor inhibitors independent role can not adjust the secretory volume of prolactin(PRL, but adenosine A 1 receptor inhibitor (DPCPX) can be one
The effect for determining blocking cordycepin in degree, makes cordycepin be significantly higher than cordycepin independent role to the inhibition of prolactin secretion
Group.The above result shows that cordycepin mediates it to significantly inhibit effect, inhibiting effect to prolactin secretion by adenosine A 1 receptor
In 25 μ g/mL of cordycepin, 100 μ g/mL of Nuciferine are the most notable, inhibiting rate 80%.
In summary, the present invention provides a kind of compositions containing cordycepin, and it is pre- to demonstrate its by animal model experiment
Anti- and treatment is fat and adjusts the effect of lipid metaboli, by the cytotoxicity of the clear compsn. consisting of influenza virus surface of In vitro cell experiment,
Hyperlipidemia can be obviously prevented, treated, pre- preventing obesity, is lost weight, is adjusted lipoprotein abnormalities, adjust lipid metaboli, reduce coronary disease
Sick incidence.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (7)
1. a kind of composition containing cordycepin, includes the raw material of following parts by weight：0.1~3 part of cordycepin, 1~12 part of Nuciferine
2. composition according to claim 1 includes the raw material of following parts by weight：0.2~2 part of cordycepin, Nuciferine 2~
10 parts.
3. any one of claim 1~2 composition is preparing prevention and/or treatment obesity, hyperlipidemia, coronary heart disease medicine
Application in object.
4. application according to claim 3, which is characterized in that the dosage form of the drug includes tablet, capsule, particle
Agent, pill, pill, oral solution, syrup and sustained-release preparation.
5. any one of claim 1~2 composition has auxiliary treatment work in preparation to obesity, hyperlipidemia and coronary heart disease
Application in food.
6. application according to claim 5, which is characterized in that the food includes ordinary food and health products.
7. any one of claim 1~2 composition has auxiliary treatment work in preparation to obesity, hyperlipidemia and coronary heart disease
Application in cosmetics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810394808.0A CN108272814A (en) | 2018-04-27 | 2018-04-27 | A kind of composition and its application containing cordycepin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810394808.0A CN108272814A (en) | 2018-04-27 | 2018-04-27 | A kind of composition and its application containing cordycepin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108272814A true CN108272814A (en) | 2018-07-13 |
Family
ID=62811886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810394808.0A Pending CN108272814A (en) | 2018-04-27 | 2018-04-27 | A kind of composition and its application containing cordycepin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108272814A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109381476A (en) * | 2018-11-26 | 2019-02-26 | 于录 | A kind of pharmaceutical composition of weight-reducing |
| CN109463730A (en) * | 2018-12-27 | 2019-03-15 | 深圳松乐生物科技有限公司 | A kind of composition containing cordycepin, liquid beverage, candy, solid beverage and tablet |
| CN112602719A (en) * | 2020-12-18 | 2021-04-06 | 江南大学 | Antibacterial composition and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106387215A (en) * | 2016-08-31 | 2017-02-15 | 宁夏朴集堂生物科技有限公司 | Radix puerariae and cordyceps militaris tea and preparation method thereof |
-
2018
- 2018-04-27 CN CN201810394808.0A patent/CN108272814A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106387215A (en) * | 2016-08-31 | 2017-02-15 | 宁夏朴集堂生物科技有限公司 | Radix puerariae and cordyceps militaris tea and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 杨菲等: "荷叶生物碱的研究进展", 《现代医院》 * |
| 陈祝安: "蝉花的生物活性成分和药理作用和保健功能", 《国宝虫草金蝉花》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109381476A (en) * | 2018-11-26 | 2019-02-26 | 于录 | A kind of pharmaceutical composition of weight-reducing |
| CN109381476B (en) * | 2018-11-26 | 2020-08-04 | 于录 | Weight-losing pharmaceutical composition |
| CN109463730A (en) * | 2018-12-27 | 2019-03-15 | 深圳松乐生物科技有限公司 | A kind of composition containing cordycepin, liquid beverage, candy, solid beverage and tablet |
| CN112602719A (en) * | 2020-12-18 | 2021-04-06 | 江南大学 | Antibacterial composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101822383B (en) | Functionality nutritional meal replacing food suitable for tumor patient and preparation method thereof | |
| US4735967A (en) | Method for desensitizing the gastrointestinal tract from food allergies | |
| JP2022036990A (en) | Intestinal health promoting compositions | |
| CN103238897A (en) | Composite plant solid drink suitable for diabetic patients | |
| CN102058888A (en) | Pharmaceutical composition for treatment of abnormal energy metabolism and application thereof | |
| WO2018090983A1 (en) | Saponin compound for improving intestinal microflora, preparation method and use thereof | |
| WO2008122190A1 (en) | The composition comprising l-carnitine or derivatives thereof and its use | |
| CN101507494A (en) | Special diet food for patient with hyperlipidemia and hypertension | |
| CN102355898A (en) | Agent for promoting energy consumption | |
| CN108272814A (en) | A kind of composition and its application containing cordycepin | |
| WO1995017889A1 (en) | Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis | |
| WO2020221184A1 (en) | Pharmaceutical composition with effect of reducing uric acid | |
| JP2008222656A (en) | Obesity ameliorating and preventing composition and health food | |
| WO2017191856A1 (en) | Antidiabetic effect of gypenoside 75 | |
| NO20001717L (en) | Serotonin-containing formulation for oral administration and use of the same | |
| WO2016124080A1 (en) | Use of 20(r)-ginsenoside rg3 in preparation of drug for preventing or/and treating obesity and drug | |
| US20060135444A1 (en) | Combination of flavonoid and procyanidin for the reduction of the mammalian appetite | |
| JPWO2005041995A1 (en) | α-Glucosidase activity inhibitor | |
| US20240197665A1 (en) | Pharmaceutical Composition For Treating Hyperlipidemia And Preparation Method Therefor | |
| CN106349318B (en) | A kind of application of pentacyclic triterpene compound in obesity treating medicine is prepared | |
| CN112457423B (en) | Natural extracted compound polysaccharide with function of improving insulin resistance and application thereof | |
| CN114916661A (en) | Natural food composition and its application | |
| WO2020063262A1 (en) | Application of 3'-deoxyinosine in preparation of drug, food or health product for multiple disease | |
| CN109364202B (en) | Composition and preparation method and application thereof | |
| CN108619283B (en) | A composition for improving lipid metabolism and reducing visceral fat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 518057 research building C411, Research Institute of Tsinghua University, Shenzhen, Nanshan District, Guangdong Applicant after: Shenzhen songzhile Biotechnology Co., Ltd Address before: 518000 research building C411, Research Institute of Tsinghua University, Shenzhen, Nanshan District, Guangdong Applicant before: SHENZHEN SONGLE BIOTECHNOLOGY Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180713 |
|
| RJ01 | Rejection of invention patent application after publication |